Bristol-Myers Squibb Company

NYSE:BMY

Drug Manufacturers - General

Healthcare
$59.56 -2.57%

-$1.42 today

Market cap
$121.75B
Beta
0.24
P/E (TTM)
15.1
EPS (TTM)
$3.56
Dividend yield
4.64%
52W Low $42.52High $62.89

Volume 9.54M

Average 11.50M

BMY Income Before Tax

Profit after all operating and non-operating items but before income tax.

Bristol-Myers Squibb CompanyNYSE: BMY

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax growth accelerates

Q2 FY2026 income before tax of $4.09B rose 130.5% year over year, ahead of the +80.6% change in trailing-twelve-month income before tax. Sequentially, it rose 26.1% from the prior quarter. Over 3 fiscal years it compounded at +6.5% a year.

Context

  • Income before tax amounted to 19.4% of revenue in FY2025, up 2.0 pp from a year earlier.
  • Income before tax increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +130.5% holds above the trailing-twelve-month pace of +80.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$4.09B+26.1% QoQ
Last fiscal yearDec 2025
$9.33B+211.3% YoY
LTMJun 2026
$11.91B+80.6% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+130.5%——
1 year+211.3%——
3-year CAGR+6.5%——
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
9.33B USD
Year-over-year change
+211.3%
4-year CAGR
+3.6%

Income Before Tax vs competitors

How BMY compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +80.6% is the 3rd highest of 11, against a peer median of +7.6%.
  • Income before tax amounts to 24.2% of revenue for BMY, versus a peer median of 18.6%.
BMY Competitors
Income Before Tax for BMY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$33.6B USD+99.3%+55.8%42.2%
JNJJohnson & JohnsonLTM Sep 2026$17.74B USD-43.7%+18.9%17.9%
NVSNovartis AGLTM Jun 2026$15.52B USD-0.5%+31.8%27.9%
AZNAstraZeneca PLCLTM Sep 2026$13.25B USD+15.8%+70.5%21.3%
ABBVAbbVie Inc.LTM Sep 2026$12.81B USD+671.9%-21.2%19.4%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$11.91B USD+80.6%+6.5%24.2%
AMGNAmgen Inc.LTM Jun 2026$10.29B USD+38.6%+6.9%27.0%
MRKMerck & Co., Inc.LTM Jun 2026$5.95B USD-69.0%+8.6%9.0%
GSKGSK plcLTM Jun 2026£5.9B GBP+27.7%+9.6%17.8%
PFEPfizer Inc.LTM Jun 2026$4.21B USD-60.0%-40.0%6.6%
GILDGilead Sciences, Inc.LTM Jun 2026-$1.96B USD-127.1%+19.0%6.4%
Peer median (excluding BMY) —+7.6%+14.3%18.6%

Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue46.39B46.16B45.01B48.3B48.2B
Cost of Revenue9.94B10.14B10.69B13.97B13.94B
Gross Profit36.45B36.02B34.31B34.33B34.26B
Gross Margin78.6%78.0%76.2%71.1%71.1%
Research & Development10.2B9.51B9.3B11.16B9.95B
Selling, General & Admin7.69B7.81B7.77B8.41B7.27B
Operating Expenses27.91B26.92B26.12B28.45B20.54B
Depreciation & Amortization10.69B10.28B9.76B9.6B4.01B
EBITDA20.12B19.22B19.37B3.17B15.23B
EBITDA Margin43.4%41.6%43.0%6.6%31.6%
Operating Income8.54B9.1B8.2B5.89B13.72B
Operating Margin18.4%19.7%18.2%12.2%28.5%
Interest Income00000
Interest Expense1.33B1.23B1.17B1.95B1.89B
Other Income / Expenses(439M)(1.39B)245M(14.27B)(4.4B)
Income Before Tax8.1B7.71B8.44B(8.38B)9.33B
Pre-Tax Margin17.5%16.7%18.8%-17.3%19.4%
Income Tax Expense1.08B1.37B400M554M2.27B
Net Income6.99B6.33B8.03B(8.95B)7.05B
Net Margin15.1%13.7%17.8%-18.5%14.6%
EPS (Basic)3.152.973.88(4.41)3.46
EPS (Diluted)3.122.953.86(4.41)3.45
Weighted Avg Shares2.22B2.13B2.07B2.03B2.04B
Weighted Avg Shares (Diluted)2.25B2.15B2.08B2.03B2.04B

Bristol-Myers Squibb Company

NYSE:BMY

Intrinsic Alpha fair value

Locked

Current Price

$59.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.